**Trader consensus heavily favors "No" at 91.5% because global surveillance systems show no signs of an emerging SARS-CoV-2 variant meeting the criteria for a Variant of Concern (VOC) in the short window remaining before 2027.** Health agencies including the WHO and ECDC continue to track only Variants Under Monitoring (VUMs) and sublineages of Omicron, such as XFG, NB.1.8.1, and the previously noted BA.3.2 ("Cicada") strain. These circulate at low to moderate levels with no evidence of substantially increased transmissibility, immune escape that evades vaccines against severe illness, or higher severity compared to recent strains. BA.3.2 detections rose in late 2025 in parts of Europe but remained minimal in U.S. surveillance (under 0.2% of sequences) and prompted no VOC designation. With roughly four and a half months left, the absence of rapid evolution toward higher-risk characteristics—combined with ongoing genomic monitoring and population immunity—supports the current pricing. A sudden shift would require unexpected data showing a new lineage driving worse outcomes or rapid dominance, which has not materialized in 2026 reporting.